Srividya Kotapati

Impact of Extended-Spectrum <i>β</i> -Lactamase–Producing <i>Escherichia coli</i> and <i>Klebsiella</i> Species on Clinical Outcomes and Hospital Costs: A Matched Cohort Study

Su Young Lee, Srividya Kotapati, Joseph L. Kuti et al. · Infection Control and Hospital Epidemiology · 2006 · 142 citations

Life Sciences, Infectious Diseases, Pharmacoeconomics +15

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial

Corneel Coens, Stefan Suciu, Vanna Chiarion‐Sileni et al. · The Lancet Oncology · 2017 · 104 citations

Pharmacy, Oncology, Immunotherapy +16

Health-related quality of life results from the phase III CheckMate 067 study

Dirk Schadendorf, James Larkin, Jedd D. Wolchok et al. · European Journal of Cancer · 2017 · 95 citations · Full text

Pharmacy, Health Sciences, Health Assessment +9

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment

Dennis A. Revicki, Alfons JM van den Eertwegh, Paul Lorigan et al. · Health and Quality of Life Outcomes · 2012 · 62 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis

Victor Barzey, Michael B. Atkins, Louis P. Garrison et al. · Journal of Medical Economics · 2012 · 51 citations

Pharmacy, Oncology, Pharmacoeconomics +17